BioCentury
ARTICLE | Clinical News

Corixa regulatory update

March 22, 1999 8:00 AM UTC

The University of Washington (Seattle, Wash.) received U.S. Patent No. 5,876,712 covering the use of autologous T cells stimulated with the Her-2/neu protein ex vivo to treat patients with cancers expressing Her-2/neu. CRXA is the exclusive licensee of the patent, and its Her-2/neu peptide vaccines have been licensed to SmithKline Beecham plc (see BioCentury Extra, Oct. 29, 1998). ...